Osimertinib is the first approved third-generation EGFR-TKI that could overcome resistance induced by first- or second-generation EGFR-TKIs and has shown a survival benefit in NSCLC patients with early-stage and metastatic disease. Here, EGFR is linked to non-small cell lung carcinoma.